Caregen (CEO Yongji Jeong), a synthetic peptide-based biotechnology company, successfully showcased its cutting-edge peptide technology and healthcare vision to the global market by participating in Vitafoods Europe 2025, the world's largest health functional food fair held in Barcelona, Spain from May 20 to 22.
This exhibition is an international exhibition that encompasses functional food raw materials, biotechnology, and the latest R&D results, with over 1,000 global companies from over 120 countries participating. On the first day of the event, May 20, Caregen held a seminar on the clinical and functional results of its peptide products, drawing great attention from industry insiders.
This seminar, in which CEO Jeong Yong-ji himself appeared as a speaker, was organized around three key products. ▲ The first, 'ProGsterol', deals with clinical approaches to metabolic diseases including type 2 diabetes and non-alcoholic steatohepatitis (MASH), and introduces a new peptide-based approach to prevent and improve metabolic diseases. ▲ The second, 'Korglutide', is an oral GLP-1 Agonist peptide (Korglutide) with the same function as the currently used injectable GLP-1 analogue obesity treatment drug, and the results of a weight loss clinical trial for Korglutide were announced. It received great attention from the relevant parties because it is an oral drug that can reduce weight without side effects. ▲ The third, Myoki, is an anti-myostatin peptide that has been proven to increase muscle mass and improve mobility. In a recent study, it was confirmed to extend the hair growth phase and improve hair loss, and it was announced that the expanded indications and related clinical trials are being prepared.
Caregen's core technology platform, Biomimetic Peptide, works by mimicking the human body's own physiological mechanism, resulting in excellent biocompatibility and safety. This technology is evaluated as a platform optimized for expansion beyond health functional foods to the medical device and pharmaceutical fields.
Based on this platform technology, Caregen's product line pursues fundamental physiological mechanism improvement rather than simple symptom improvement, and has opened a new market horizon called 'Premium Nutraceutical' by securing scientific precision that goes beyond the efficacy limits of health functional foods.
A European healthcare company buyer who attended the seminar commented, “Caregen’s solution is very impressive in that it targets key health issues across all generations, such as blood sugar, weight, muscles, and hair, and provides scientifically proven answers rather than simple ingredients.”
During the exhibition period, numerous global buyers and partners visited the Caregen booth and held active business meetings. Caregen plans to use this as an opportunity to accelerate its strategic expansion in the global market, including Europe.
CEO Jeong Yong-ji said, “Caregen’s mission is to solve practical health concerns that all generations commonly experience through technology-driven innovation,” and added, “We will continue to develop and introduce new peptide-based solutions across various fields in the future.”
Through its participation in Vitafoods Europe 2025, Caregen has once again demonstrated that it is positioning itself as an integrated healthcare solutions company that improves the quality of life of people around the world, rather than simply being a technology-focused company.
- See more related articles
You must be logged in to post a comment.